Bispecific antibody treatment for neuroblastoma and diffuse midline glioma in children
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma
['FUNDING_U01'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11136286
A new antibody that connects a child's T cells directly to tumor cells to help treat neuroblastoma and diffuse midline glioma.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11136286 on ClinicalTrials.gov |
What this research studies
Researchers are developing bispecific T cell engager antibodies that bind both tumor cells and a child’s T cells to stimulate immune killing. They plan to use self-disassembling polymeric chemokines to draw more T cells into solid tumors and test how the antibody can cross the blood–brain barrier to reach brain tumors. The team uses patient-derived tumor samples and mouse models to study effectiveness and understand how the therapies work. If promising, these approaches aim to move toward options for children with tumors that cannot be removed or have spread.
Who could benefit from this research
Good fit: Children diagnosed with neuroblastoma or diffuse midline glioma, especially those with unresectable or metastatic disease, would be the most relevant candidates.
Not a fit: Patients whose tumors do not express the specific targets recognized by the antibody or who cannot tolerate immune-based therapy may not benefit from this approach.
Why it matters
Potential benefit: This approach could help immune cells reach and kill tumor cells, offering new treatment options for children with hard-to-treat neuroblastoma or diffuse midline glioma.
How similar studies have performed: Bispecific T cell engagers have shown clear success in some blood cancers but applying them to pediatric solid and brain tumors is newer and less established.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLSON, JAMES M — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: OLSON, JAMES M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.